INVESTIGATION OF ANTI-THYROPEROXIDASE ANTIBODY (anti-TPO Ab) AND THYROID HORMONES IN HYPERTHYROIDISM

Abstract

This study conducted at the Al Kindi Educational Hospital in Baghdad involved 100 participants, consisting of 50 healthy individuals and 50 patients diagnosed with hyperthyroidism. Both groups were evenly divided, with 25 men and 25 women in each. The baseline control data for the healthy individuals were collected between January 2022 and April 2023 within the same facility. All participants underwent testing for thyroid function markers, specifically TSH (Thyroid Stimulating Hormone), FT4 (Free Thyroxine), and Anti-TPO Ab (Antithyroid Peroxidase Antibodies). The study's findings revealed a significant gender-related disparity in hyperthyroidism. Females, whether in the patient or control group, exhibited the most pronounced increase in thyroid-related markers, with a highly significant increment (P ≤ 0.01) compared to their male counterparts. In contrast, no significant differences were observed between male patients and male controls, nor between female patients and female controls in the context of hyperthyroidism. Furthermore, the research highlighted specific biomarkers, Anti-TPO Ab and Free T4, which exhibited a highly significant increment (P ≤ 0.01) in hyperthyroid patients compared to the control group. However, TSH levels remained relatively consistent between the two groups, showing no significant differences. The aim of the study is to investigate the relationship between anti-thyroperoxidase antibody (anti-TPO Ab) levels and thyroid hormone concentrations in individuals with hyperthyroidism